SMAD4 and hepatocellular carcinoma: In fact, the treatment with exosomes from HCC patients’ sera or HCC cell lines reduced the levels of these proteins, whereas the incubation with exosomes from anti-miR-210 transfectants did not change SMAD4 and STAT6 levels, reducing the tube formation capability in HUVECs instead.